Cyclooxygenase (COX)-2, the protein that plays a key role in gastric carcinogenesis, is being evaluated as a pharmacological target for both the prevention and treatment of cancer [1, 2] . Tumor promotion may be attributed to the stimulation of cell proliferation and migration, the inhibition of apoptosis, the increase in malignant cell invasiveness and the induction of angiogenesis [1] [2] [3] .
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prostaglandin D 2 from precursor prostaglandin H 2 , synthesized by COX-2) decreased as gastritis became more severe.
Moreover, there was a weak correlation between COX-2 expression scores and presence of atrophic gastritis, intestinal metaplasia, or dysplasia in patients with chronic gastritis (x 2 = 6.98, P<0.10).
In conclusion, COX-2 expression scores exhibited considerable variation among the three groups for severity of gastritis, tending to increase from mild to moderate gastritis states and to decrease from moderate to severe gastritis states, while there was a weak association between COX-2 expression scores and precancerous lesions in patients with chronic gastritis. 
